Savara (SVRA) Stock Price, News & Analysis

Savara logo
$4.26 -0.95 (-18.23%)
Closing price 03:59 PM Eastern
Extended Trading
$4.29 +0.03 (+0.80%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Savara Stock (NASDAQ:SVRA)

Advanced

Key Stats

Today's Range
$4.00
▼
$4.52
50-Day Range
$4.22
▼
$5.45
52-Week Range
$4.00
▼
$7.01
Volume
17.01 million shs
Average Volume
3.02 million shs
Market Capitalization
$939.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.14
Consensus Rating
Moderate Buy

Company Overview

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options.

Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.

Molgramostim is investigational; its availability and development status may change as clinical and regulatory work progresses. Savara’s business is centered on advancing this program and evaluating its potential to address unmet needs in rare respiratory disease.

AI Generated. May Contain Errors.

Savara Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

SVRA MarketRank™: 
2.663358147225 of 5 stars

Savara scored higher than 53% of companies evaluated by MarketBeat, and ranked 414th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Savara has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Savara has a consensus price target of $10.14, representing about 138.1% upside from its current price of $4.26.

  • Amount of Analyst Coverage

    Savara has only been the subject of 4 research reports in the past 90 days.

  • Read more about Savara's stock forecast and price target.
  • Earnings Growth

    Earnings for Savara are expected to grow in the coming year, from ($0.68) to ($0.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Savara is -6.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Savara is -6.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Savara has a P/B Ratio of 8.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    16.59% of the float of Savara has been sold short.
  • Short Interest Ratio / Days to Cover

    Savara has a short interest ratio ("days to cover") of 12.94, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Savara has recently increased by 12.30%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Savara does not currently pay a dividend.

  • Dividend Growth

    Savara does not have a long track record of dividend growth.

  • News Sentiment

    Savara has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 22 news articles for Savara this week, compared to 3 articles on an average week.
  • Search Interest

    5 people have searched for SVRA on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • MarketBeat Follows

    12 people have added Savara to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Savara insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    5.30% of the stock of Savara is held by insiders.

  • Percentage Held by Institutions

    87.93% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Savara's insider trading history.
Receive SVRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SVRA Stock News Headlines

Savara Says FDA Likely To Miss Molgramostim Review Deadline
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Savara Inc. (SVRA) Shares Are Taking Off. Here’s What’s Coming
See More Headlines

SVRA Stock Analysis - Frequently Asked Questions

Savara's stock was trading at $6.03 on January 1st, 2026. Since then, SVRA shares have decreased by 29.4% and is now trading at $4.26.

Savara Inc. (NASDAQ:SVRA) announced its quarterly earnings results on Monday, November, 9th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.01.

Savara's top institutional shareholders include Nantahala Capital Management LLC (3.24%), State Street Corp (3.01%), Marshall Wace LLP (2.89%) and Pictet Asset Management Holding SA (1.31%). Insiders that own company stock include Matthew Pauls, David L Lowrance, Joseph S Mccracken, Richard J Hawkins and Nevan C Elam.
View institutional ownership trends
.

Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Savara investors own include NVIDIA (NVDA), Tesla (TSLA), Viking Therapeutics (VKTX), Solid Biosciences (SLDB), ADMA Biologics (ADMA), Cidara Therapeutics (CDTX) and Citius Pharmaceuticals (CTXR).

Company Calendar

Last Earnings
11/09/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SVRA
Previous Symbol
AMEX:ANX
CIK
1160308
Employees
70
Year Founded
1995

Price Target and Rating

High Price Target
$12.00
Low Price Target
$9.00
Potential Upside/Downside
+138.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.61)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$118.84 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-96.87%
Return on Assets
-74.22%

Debt

Debt-to-Equity Ratio
0.28
Current Ratio
8.55
Quick Ratio
8.55

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.49 per share
Price / Book
8.69

Miscellaneous

Outstanding Shares
220,620,000
Free Float
208,931,000
Market Cap
$939.84 million
Optionable
Optionable
Beta
0.32

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:SVRA) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners